THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA;THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; AS REPRESENTED BY THE SECRETARY;THE UAB RESEARCH FOUNDATION;THE UNITED STATES OF AMERICA; DEPARTMENT OF HEALTH AND HUMAN SERVICES;VANDERBILT UNIVERSITY
发明人:
MALONEY, DAVID J.,WATERSON, ALEX GREGORY,BANTUKALLU, GANESHA RAI,BRIMACOMBE, KYLE RYAN,CHRISTOV, PLAMEN,DANG, CHI V.,DARLEY-USMAR, VICTOR M.,HALL, MATTHEW,HU, XIN,JADHAV, AJIT,JANA, SOMNATH,KIM, KWANG
申请号：
CA3029489
公开号：
CA3029489A1
申请日:
2017.06.29
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The disclosure provides a compound of the formula (II) and pharmaceutically acceptable salts thereof. The variables, e.g. n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful for treating cancer and fibrosis. The compounds may be particularly useful for treating forms of cancer in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred. The disclosure also provides pharmaceutical compositions containing a compound of this formula and method for treating patients having cancer, fibrosis, or other conditions in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred.
